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Croton celtidifolius Baill is a tree found in the Atlantic Forest South
of Brazil, mainly in Santa Catarina. The bark and leaf infusions of
this medicinal plant have been popularly used for the treatment of
inflammatory diseases. The anti-aggregant activity of C.
celtidifolius crude extract (CE) and the column chromatography
(CC) isolated compounds flavonoids, catechin and gallocatechin
were evaluated in human blood platelets. The platelet-rich plasma
(PRP) was incubated with different concentrations of flavonóides
(50 - 200 µg/mL) to be tested before platelet aggregation was
induced by the agonists adenosine 5´diphosphate (ADP) and
collagen. At 200 µg/mL the CE, catechin and gallocatechin
markedly inhibited platelet aggregation with the aggregant agents.
Using ATP production as an index of platelet secretory capacity,
we observed a decreased production of ATP in platelets treated
with flavonoids when stimulated by collagen. On the other hand,
the flavonoids did not promote inhibitory effect on prothrombin
time (PT), thromboplastin time (APTT) and thrombin time (TT).
In conclusion, these observations suggest that C. celtidifolius is
likely to exert an inhibitory action on platelets in vitro by
suppressing secretion and platelet aggregation.
*Correspondence:
T. J. C. Neiva
Departamento de Análises Clínicas -
CCS
Universidade Federal de Santa
Catarina
Campus Universitário - Trindade









Activation of platelets plays a key role in haemostasis
and circulation. Platelet aggregation is known to be a result
of complex signal transduction cascade reactions brought
about by stimulants. After activation, platelets provide a
catalytic membrane surface for thrombin generation, which
accelerates the formation of fibrin, necessary to stabilize
thrombin. Key to these events is the presence, on the platelet
surface, of receptors that can respond rapidly to soluble
agonists, including collagen, thrombin and adenosine
5‘diphosphate (Bluestein, 2004; Massberg et al., 2005).
Platelet dysfunction contributes in the development and
progression of many cardiovascular diseases like arterial
hypertension, atherosclerosis and thrombosis. Indeed, it has
been reported that patients with hypertension or coronary
heart disease tend to have increased platelet reactivity
(Hernández Hernández et al., 1997; Maeda, Bydlowski and
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Lopes, 2005). Other studies in hypertensive patients
showed that platelets were more sensitive to thrombin
(Andrioli et al., 1996; Görlach et al., 2005) and exhibited
an elevation in their intracellular free calcium (Erne et al.,
1984; Bruschi et al., 1985). This later may potentiate the
platelet activity and increase the risk of thrombosis.
Therefore, many investigations were carried out in order to
prevent this abnormal hyperactivity of platelets reported in
cardiovascular disorders by using different therapies,
including use of medicinal plants. In fact, it has been shown
that some plants, such as garlic (Rahman and Billington,
2000) and tomato (Dutta-Roy, Crosbie and Gordon, 2001),
may be beneficial in protecting against cardiovascular
diseases as a result of the platelet aggregation inhibition.
There are many nutritive and non-nutritive compounds
present in the diet that may affect platelet function in
various ways. Therefore, the compounds that inhibit
platelet function are of great interest. In fruits and
vegetables, there are many bioactive compounds, such as
polyphenolic, vitamins and carotenoids (Olas et al., 2005;
Rechner and Kroner, 2005).
Flavonoids represent an interesting group of
polyphenols natural compounds found ubiquitously in the
plant-derivated constituents on the human diet and many
studies indicates that certain flavonoids have been shown
to modify eicosanoids synthesis (antiprostanoid and
antiinflammatory responses), protect low-density
lipoprotein from oxidation, preventing atherosclerotic
plaque formation, and prevent platelet aggregation (Cody,
1988; Coni et al., 2000; Olas et al., 2005).
Croton celtidifolius Baill, commonly known as “San-
gue-de-adave” is a tree found in the South Atlantic Forest of
Brazil, mainly in Santa Catarina State. The bark and leaf
infusions of this medicinal plant have been popularly used for
the treatment of ulcer, rheumatism and other inflammatory
diseases. Several compounds with pharmacological activity
have been previously isolated from other Croton spp. It has
been reported that latex of C. lechleri contains the alkaloid
taspine, which may be the active principle responsible for the
anti-inflammatory (Vaisberg et al., 1989) and anti-
tumourogenic activity (Chen, Cai and Phillipson, 1994) of
this plant. However, studies about chemical constituents, as
well as pharmacological effects of C. celtidifolius, are still
limited. Recently, Nardi et al. (2003) showed that CE of C.
celtidifolius and two isolated compounds, catechin and
gallocatechin, have significant anti-inflammatory and
antioxidant activity. Nevertheless, there is no information
about the eventual influence of this medicinal plant on
haemostasis. The haemostatic system depends on the
interaction between wall of sanguineous vase and platelets
circulating factors. The platelets reactions as aggregation,
peroxidation and secretion are considered as a primary
replay. The proteins that participate in the coagulation
process are enclosed in the reply and will play in the
haemostatic regulation. Thus, the purpose of the present
study was to investigate the effects of C. celtidifolius CE and
the isolated compounds, catechin and gallocatechin, in
platelet activity and in coagulation.
MATERIALS AND METHODS
Plant material
C. celtidifolius Baill was collected in March, 2000,
from Orleans city, SC, Brazil. The voucher specimen was
identified with the collection documenting number 31272
at the Bottany Department, UFSC, by Prof. Dr. Daniel de
Barcelos Falkenberg and deposited in the author’s
laboratory.
Extraction and isolation
The extraction and isolation of the catechin and
gallocatechin were performed as described previously (Nardi
et al., 2003). Air-dried bark (154 g) was chopped into small
pieces and extracted three times with 250mL of 80% aqueous
EtOH at room temperature. The combined extracts were
filtered and the solvent was evaporated in a vacuum to give
42,9 g of the crude hydroalcoolic extract (EB). The crude
hydroalcoolic extract was successively partitioned with
ether, ethyl acetate and n-butanol. The ethyl acetate fraction
was chromatographed over a column of silica gel water
(20%) inactivated and eluted with hexane/acetate gradient.
The first fractions containing catechin and gallocatechin
were further purified by flash chromatography using hexane
40%/EtOAc 59%/AcOH 1% as isocratic eluent.
Reagents
Adenosine diphosphate (ADP), collagen and
luciferin/luciferase were purchased from Chronolog
Corpration, USA. Thromboplastin (PT test), elagic
phospholipide (APTT test) and thrombin reagents were
purchased from Organon Technika, Durham, NC, USA.
Subjects
The study was approved by the Ethics Committee of
the University, UFSC, Florianópolis, SC, Brazil, and
included 15 healthy volunteers who gave written informed
consent to participate, process 150-03/2002.
Isolation of platelets
Platelet rich plasma (PRP) was prepared by
centrifugation of citrated blood at 22 °C for 6 min. at 400g.
Platelets were adjusted to 3.0 x 108cell/mL with sterile saline.
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Measurement of platelet aggregation (PA)
PA was determined by the turbidimetric method (Born,
Cross, 1963) using a Chronolog Aggregometer. Aliquots of
400 µL of a platelet suspension were transferred into a small
cuvette and stirred at a constant speed of 180 g at 37 °C. The
platelets were pre-incubated with different fractions of CE,
catechin, gallocatechin or vehicle (1mM-NaOH) for 5 min
at 37 °C, before the addition of aggregant agents. The extent
of aggregation (%) was recorded continually for 5 min after
addition of the agonists.
Measurement of platelet secretion induced by collagen
Platelet secretion (%) was evaluated using the system
luciferin/luciferase according Pascual and Romay (1992).
The platelets were pre-incubated with different
concentrations of compounds or with the vehicle (1 mM-
NaOH) for 5 min at 37 °C, before the addition of 4 µg/mL
of collagen.
Measurement of blood coagulation
Human blood was obtained from 15 individual
healthy donors without history of bleeding or thrombosis.
Nine parts of blood collected by venipuncture were drawn
into one part of 3,8% trisodium citrate. Blood was
centrifuged for 10 min at 900g, and the plasma stored at -
20 °C until were tested. Activated prothrombin time (PT),
activated partial thromboplastin time (APTT) and
thrombin time (TT) were evaluated according to Triplett et
al. (1978). The plasma was pre-incubated with different
concentrations of inhibitors or vehicle (1mM-NaOH) for 2
min at 37 °C and coagulation time was measured using a
Net Lab Digital Coagulation System.
Statistical Analysis
Data were expressed as mean ± SD. The Tukey-
Krammer test was employed to determine differences
between the groups. Differences were considered
significant when the probability was p < 0,05. The
statistical program Instat-2 was utilized.
RESULTS AND DISCUSSION
Many different herbal components in folk medicine are
antiplatelet agents that inhibit platelet activation and have
been used in the management of cardiovascular disorders.
The objective of the present study was to determine whether
C. celtidifolius would affect platelet function and blood
coagulation. A control aggregation test induced by collagen
or ADP was systematically carried out in the beginning of
each experiment in order to verify the good physiological
status of platelets. Human blood platelets were incubated in
the presence of CE, catechin and gallocatechin for 5 min at
37 °C. Using 200 µg/mL of CE, or of its isolated compounds,
was sufficient to exhibit a significant inhibition by two types
of agonists. The effect of CE, catechin and gallocatechin on
platelet aggregation induced by collagen is shown in Table
I. Treatment with 200 µg/mL of CE, catechin and
gallocatechin were sufficient to induce a significant inhibition
of 75%, 60% and 65% respectively. Subsequently, we
examined the effect of these flavonoids in the presence of
ADP. The results obtained with these compounds were
sufficient to exhibit a potent inhibitory effect on platelet
aggregation induced by this agonist (Table II). The results
obtained from the platelet aggregation study demonstrated
that C. Celtifoulius promoted changes in platelet metabolism
with inhibitory effect of the primary hemostasis. We
observed, in PRP, that the shape change and the primary
platelet aggregation phase induced by the two agonists was
not affected in the presence of these flavonoids, on the other
hand, the second platelet aggregation phase was significantly
inhibited.
In the current study, we have found that the inhibitory
effect were, in all cases, dose dependent at concentrations
between 50 - 200 µg/mL. Platelet aggregation is known to be
a result of complex signal transduction cascade reactions
brought about by stimulants. Blood platelets contain three
types of secretory organelles: lysosomes, α-granules and dense
granules. In these secretory organelles, there are different
biologically relevant molecules that are released in response to
TABLE I - Effects of Croton celtidifolius Baill, crude
extract (CE), catechin and gallocatechin on platelet
aggregation induced by 4µg/mL of collagen.
Treatment Collagen (%)
Control (1mM-NaOH) 83.0 ± 1.8
CE 50 µg/mL 78.2 ± 3.9
100 µg/mL 60.0 ± 3.0*
200 µg/mL 20.4 ± 1.8**
Catechin 50 µg/mL 68.2 ± 3.8
100 µg/mL 50.0 ± 5.0*
200 µg/mL 32.4 ± 4.0**
Gallocatechin 50 µg/mL 68.0 ± 7.0
100 µg/mL 39.7 ± 7.0**
200 µg/mL 29.0 ± 6.0**
Statistical: Tukey Kramer test n=15, p < 0.05*; p < 0.001**
Platelets were pre-incubated with each compound for 5min.
at 37 0C before stimulation. Each value represents the mean
± SD of 15 independent experiments.
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platelet agonists, like thrombin or collagen. The platelet
secretory process plays a key role in thrombosis. Moreover,
platelets play a very important role in the pathogenesis of
cardiovascular diseases and at the site of injury or in
atherosclerosis vessel wall stability of atherosclerotic plaques
(Varughese, Lip, 2005; Vorchheimer, Becker, 2006). Using
ATP production as an index of platelet secretion capacity, we
observed a decreased platelet ATP production. A significant
effect was observed after cells were incubated with the
flavonoids at a concentration of 200 µg/mL (Table III). The
second platelet aggregation phase, which is dependent on
platelet secretion, let us to conclude that the reaction release
inhibition could be, in this study, the mechanism involved in the
antiaggregatory effects of these compounds. Our results are in
agreement with many studies that have shown that flavonoids
significantly inhibited platelet adhesion, aggregation and
secretion (Polette et al., 1996; Mardla, Kobzar, Samel, 2004;
Guglielmone et al., 2005; Vitseva et al., 2005). Polette et al.
(1996) reported that catechins inhibited N-3 fatty acid-induced
aggregation in washed platelets. Furthermore, the most
frequently studied flavonoid, quercetin, has been shown to
have biological properties consistent with a sparing effect on
the cardiovascular system. Quercetin and other flavonoids
modify eicosanoid biosynthesis, prevent platelet aggregation
and promote relaxation of cardiovascular smooth muscle
(Cody, 1988; Mardla, Kobzar, Samel, 2004). The results
obtained in the present study demonstrate that both, catechin
and gallocatechin, were effective in preventing platelet
aggregation in the presence of two agonists.
Finally, to evaluate the effects of flavonoids on the
enzymes of blood coagulation, screening tests were carried
out in relation to activated PT, activated partial APTT and
TT. High concentration of flavonoids (200 µg/mL) did not
increase the clotting time of the three parameters evaluated
under the experimental conditions (Table IV). It is worth
noting that the pre-incubation of plasma at a maximum
TABLE III - Effects of Croton celtidifolius Baill, crude
extract (CE), catechin and gallocatechin on platelet
secretion stimulated by 4 µg/mL collagen.
Treatment Secretion (%)
Control (1mM-NaOH) 100 ± 0.0**
CE 50 µg/mL 73.3 ± 4.0**
200 µg/mL 43.3 ± 4.1**
Catechin 50 µg/mL 83.0 ± 2.6**
200 µg/mL 42.0 ± 2.0**
Gallocatechin 50 µg/mL 72.0 ± 1.5**
200 µg/mL 36.3 ± 6.6**
Statistical: Tukey Kramer test n=5, p < 0.05*; p < 0.001**
Platelets were pre-incubated with each compound for 5 min
at 37 0C before stimulation. Each value represents the mean
± SD of 5 independent experiments.
TABLE II - Effects of Croton celtidifolius Baill, crude
extract (CE), catechin and gallocatechin on platelet
aggregation induced by 6 µM of ADP.
Treatment ADP(%)
Control (1mM-NaOH) 71.0 ± 3.4**
CE 50 µg/mL 68.3 ± 4.8**
100 µg/mL 53,8 ± 2.7**
200 µg/mL 17.6 ± 2.3**
Catechin 50 µg/mL 70.0 ± 3.0**
100 µg/mL 60.4 ± 2.0**
200 µg/mL 40.0 ± 1.4**
Gallocatechin 50 µg/mL 61.0 ± 3.1**
100 µg/mL 24.0 ± 3.3**
200 µg/mL 15.5 ± 1.4**
Statistical: Tukey Kramer test n=15, p < 0.05*; p < 0.001**
Platelets were pre-incubated with each compound for 5 min
at 37 0C before stimulation. Each value represents the mean
± SD of 15 independent experiments.
TABLE IV - Effects of Croton celtidifolius Baill, crude
extract (CE), catechin and gallocatechin (200µg/mL) on
prothrombin time (PT), partial thromboplastin time (APTT)
and thrombin time (TT). The plasma was incubated with each
compound for 5 min. at 37 0C. Each value represents the
mean ± SD of 6 independent experiments.
Test/ Treatment Time (s)
PT/
Control 12.4 ± 0.5
CE 11.8 ± 0.5
Catechin 11.4 ± 0.6
Gallocatechin 12.1 ± 0.3
APTT/
Control 40.0 ± 1.8
CE 40.3 ± 2.0
Catechin 41.2 ± 1.0
Gallocatechin 41.6 ± 1.4
TT/
Control 15.5 ± 0.3
CE 14.4 ± 0.2
Catechin 14.0 ± 0.2
Gallocatechin 14.8 ± 0.3
Statistical: Tukey Kramer test n= 6 p > 0.05
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dosage (200 µg/mL) did not promote inhibitory action on
fibrinogen as observed on TT. In addition, neither had an
inhibitory effect upon the activity of the other plasma
proteins as measured by PT and APTT.
CONCLUSION
The obtained data demonstrate that the activity of C.
celtidifolius crude hidroalcoolic extract and its isolated
compounds, catechin and gallocatechin, are limited to
primary haemostasis in human blood. However, future
studies are necessary to elucidate the biochemical platelet
al.terations which are associated with the effects of these
compounds to promote inhibition of platelet secretion and
aggregation
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RESUMO
Atividade antiplaquetária do Croton celtidifolius
Croton celtidifolius Baill é uma árvore encontrada na Mata
Atlântica, no sul do Brasil, principalmente no estado de
Santa Catarina. A infusão da casca e folhas dessa planta
medicinal é utilizada na medicina popular para o tratamen-
to de doenças inflamatórias. A atividade antiagregante do
extrato bruto de C. celtidifolius (CE) e de seus flavonóides
isolados por coluna cromatográfica (CC), catequina e
galocatequina, foi avaliada em plaquetas humanas. O plas-
ma rico em plaquetas (PRP) foi incubado com diferentes
concentrações dos flavonóides testados (50 - 200 µg/mL)
e posteriormente a agregação foi induzida pelos agonistas
adenosina 5’difosfato (ADP) e colágeno. Na concentração
de 200 µg/mL o CE, a catequina e a galocatequina inibiram
a agregação plaquetária induzida pelos agonistas. A pro-
dução de ATP foi utilizada como um índice de capacidade
de secreção plaquetária e observamos uma diminuição na
produção de ATP nas plaquetas tratadas com os
flavonóides e estimuladas com o colágeno. Por outro lado,
os flavonóides não promoveram um efeito inibitório no tem-
po de protrombina (PT), tempo de tromboplastina parcial
ativada (APTT) e tempo de trombina (TT). Essas observa-
ções sugerem que o C. celtidifolius exerce, in vitro, uma
ação inibitória nas plaquetas através da inibição da secre-
ção e agregação plaquetária.
UNITERMOS:  Croton celtidifolius. Agregação
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